John Simard, a director and 10% owner of XBiotech Inc. (NASDAQ:XBIT), filed a Form 4 on October 28, 2026, disclosing the purchase of 368,524 shares of common stock on October 26, 2026, at a price of $1.93 per share.

Key Highlights

  • Purchase date: The transaction occurred on October 26, 2026.
  • Shares acquired: Simard acquired 368,524 shares of XBiotech common stock, coded as a purchase (P).
  • Transaction price: The shares were acquired at $1.93 each.
  • Post-transaction ownership: Following the transaction, Simard directly beneficially owns 4,191,690 shares of common stock.
  • Seller identified: According to the filing's remarks, Simard purchased the shares from Thorpe McKenzie.
  • Roles disclosed: Simard is identified in the filing as both a Director and a 10% Owner of XBiotech Inc.

Simard's Direct Purchase From Thorpe McKenzie

According to the Form 4 filed with the U.S. Securities and Exchange Commission, John Simard acquired 368,524 shares of XBiotech Inc. common stock on October 26, 2026. The filing records the transaction code as "P," denoting an open-market or privately negotiated purchase, at a stated price of $1.93 per share. The filing's remarks section notes that "Mr. Simard purchased the shares from Thorpe McKenzie," identifying the counterparty by name.

Simard is listed in the filing as both a Director and a 10% Owner of XBiotech Inc., which trades on NASDAQ:XBIT. The filing was signed and submitted on October 28, 2026, two days after the reported transaction date. No derivative securities transactions were reported in Table II of the filing.

Following the reported purchase, the filing states that Simard directly and beneficially owns 4,191,690 shares of XBiotech common stock. No indirect ownership or derivative positions are reported. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) trading plan, as the corresponding checkbox on the form is not checked.

What Was Disclosed

The filing discloses a single purchase of 368,524 shares of XBiotech Inc. common stock by director and 10% owner John Simard on October 26, 2026, at $1.93 per share, acquired from Thorpe McKenzie, bringing his direct beneficial ownership to 4,191,690 shares.